Investigational Drug Details
| Drug ID: | D233 |
| Drug Name: | MSDC-0602K |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | 87355566 |
| CasNo: | 1314533-27-1 |
| Repositioning for NAFLD: | No |
| SMILES: | C(C1SC(=O)NC1=O)c1ccc(cc1)OCC(=O)c1cc(OC)ccc1.[K] |
| Structure: |
|
| InChiKey: | WUPYCVYXBXCSQK-UHFFFAOYSA-N |
| Molecular Weight: | 411.52 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | MPC modulator |
| Therapeutic Category: | Antidiabetic drug |
| Clinical Trial Progress: | Phase 2 completed (MSDC-0602K did not demonstrate statistically significant effects on primary and secondary liver histology endpoints. However, effects on non-invasive measures of liver cell injury and glucose metabolism support further exploration of MSDC-0602K's safety and potential efficacy in patients with type 2 diabetes and liver injury. [ClinicalTrials.gov Identifier: NCT02784444].) |
| Latest Progress: | Failed in clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0152 | NCT02784444 | Phase 2 | Completed | Has Results | September 14, 2016 | September 16, 2020 | Details |
| L0173 | NCT03970031 | Phase 3 | Not yet recruiting | No Results Available | June 2022 | July 12, 2021 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | Details |
| A03385 | 34022222 | J Biol Chem | Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. | Details |
| A07128 | 32610115 | J Hepatol | Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. | Details |
| A08948 | 31928475 | Expert Opin Investig Drugs | NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root. | Details |
| A09548 | 31697972 | J Hepatol | Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. | Details |
| A13493 | 29950116 | Expert Opin Investig Drugs | MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. | Details |